
BIOX Stock Forecast & Price Target
BIOX Analyst Ratings
Bulls say
Bioceres Crop Solutions is projecting FY24 revenues of $464.8 million, representing an 11% year-over-year growth, driven by a significant 46% growth in HB4 sales and improved applications in crop protection. The company anticipates approximately 20% annual EBITDA growth, supported by the expansion of HB4 Soy acreage in Brazil and increasing manufacturing capabilities in crop protection and nutrition, which will enhance margins from 20% to the target of 25%. Additionally, with a robust crop productivity franchise and opportunities for geographic expansion, Bioceres expects mid-teens organic growth and a shift towards mid-20% AEBITDA margins, particularly fueled by the adoption of drought-resistant seed technologies in the large Brazilian market.
Bears say
Bioceres Crop Solutions Corp faces a challenging financial landscape characterized by a revision of growth expectations, with the company now projecting mid-teens growth, down from prior targets of over 20%. The decreased adjusted EBITDA performance, primarily due to elevated operating expenses and a decline in key revenue sources such as the Syngenta accrual, has contributed to a negative outlook on profitability. Additionally, industry challenges have led to a decrease in gross margins and ongoing concerns regarding the viability of the company's low-margin grain sales impacting overall financial results.
This aggregate rating is based on analysts' research of Bioceres Crop Solutions Corp and is not a guaranteed prediction by Public.com or investment advice.
BIOX Analyst Forecast & Price Prediction
Start investing in BIOX
Order type
Buy in
Order amount
Est. shares
0 shares